Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Investigational New Drugs, (2013), 31, 5, (1265-1274), 10.1007/s10637-012-9910-y)

Tetsuhide Ito, Takuji Okusaka, Toshirou Nishida, Kenji Yamao, Hisato Igarashi, Chigusa Morizane, Shunsuke Kondo, Nobumasa Mizuno, Kazuo Hara, Akira Sawaki, Satoshi Hashigaki, Nobuyuki Kimura, Mami Murakami, Emiko Ohki, Richard C. Chao, Masayuki Imamura

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original publication of this article, the license subtype should be CC BYand not CC BY-NC. The original article has been corrected.

Original languageEnglish
JournalInvestigational New Drugs
DOIs
Publication statusAccepted/In press - 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor (Investigational New Drugs, (2013), 31, 5, (1265-1274), 10.1007/s10637-012-9910-y)'. Together they form a unique fingerprint.

Cite this